A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Sponsor
AbbVie
Study ID
NCT03219437
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • risankizumab — DRUG
    subcutaneous (SC) injection
  • methotrexate — DRUG
    capsule

Study Details

The purpose of this study is to compare the safety and efficacy of risankizumab to methotrexate in participants with moderate to severe plaque psoriasis.

Key Dates

Start date
Jul 30, 2018
Status verified
Nov 2022
Primary completion
Nov 26, 2021
Completion
Nov 26, 2021

Study Design

Enrollment
104 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Methotrexate
    Participants to receive double-blind methotrexate.
  • Experimental: Risankizumab
    Participants to receive double-blind risankizumab.

Primary Outcome Measure

Percentage of participants with Static Physician Global Assessment (sPGA) score of clear or almost clear (0, 1) at Week 28. [ Time Frame: Week 28 ]

Related Studies